Mark Okusa (University of Virginia School of Medicine)
In search for better CKD drugs, researchers propose a new-ish target for the disease
In the past few years, three new drugs for CKD have emerged on the market: J&J’s Invokana, AstraZeneca’s Farxiga — both SGLT2 inhibitors — and more recently …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
